AstraZeneca (AZN)
NASDAQ: AZN
· Real-Time Price · USD
73.76
0.23 (0.31%)
At close: Sep 26, 2025, 3:59 PM
73.75
-0.01%
After-hours: Sep 26, 2025, 07:45 PM EDT
AstraZeneca Revenue Breakdown
| Period Ending | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2019 |
|---|---|---|---|---|
| Bevespi Revenue | 15M | 11M | 13M | 389M |
| Bevespi Revenue Growth | +36.36% | -15.38% | -96.66% | n/a |
| BioPharmaceuticals: total Respiratory & Immunology Revenue | 1.48B | 654M | 56M | 141M |
| BioPharmaceuticals: total Respiratory & Immunology Revenue Growth | +126.76% | +1067.86% | -60.28% | n/a |
| Breztri Revenue | 163M | 53M | 375M | 377M |
| Breztri Revenue Growth | +207.55% | -85.87% | -0.53% | n/a |
| Brilinta Revenue | 331M | 185M | 95M | 167M |
| Brilinta Revenue Growth | +78.92% | +94.74% | -43.11% | n/a |
| Bydureon Revenue | 43M | 62M | 280M | 267M |
| Bydureon Revenue Growth | -30.65% | -77.86% | +4.87% | n/a |
| Calquence Revenue | 653M | 396M | 3M | 338M |
| Calquence Revenue Growth | +64.90% | +13100.00% | -99.11% | n/a |
| Crestor. Revenue | 280M | 16M | 732M | 283M |
| Crestor. Revenue Growth | +1650.00% | -97.81% | +158.66% | n/a |
| Daliresp-Daxas Revenue | 17M | 54M | 320M | 393M |
| Daliresp-Daxas Revenue Growth | -68.52% | -83.12% | -18.58% | n/a |
| Enhertu Revenue | 67M | 18M | 105M | 116M |
| Enhertu Revenue Growth | +272.22% | -82.86% | -9.48% | n/a |
| Farxiga Revenue | 1.5B | 275M | 604M | 333M |
| Farxiga Revenue Growth | +447.27% | -54.47% | +81.38% | n/a |
| Fasenra Revenue | 406M | 230M | 39M | 585M |
| Fasenra Revenue Growth | +76.52% | +489.74% | -93.33% | n/a |
| Faslodex Revenue | 78M | 5M | 588M | 784M |
| Faslodex Revenue Growth | +1460.00% | -99.15% | -25.00% | n/a |
| Imfinzi Revenue | 1.08B | 374M | 336M | 197M |
| Imfinzi Revenue Growth | +187.70% | +11.31% | +70.56% | n/a |
| Kanuma Revenue | 46M | 20M | 99M | 20M |
| Kanuma Revenue Growth | +130.00% | -79.80% | +395.00% | n/a |
| Koselugo Revenue | 80M | 47M | 167M | 64M |
| Koselugo Revenue Growth | +70.21% | -71.86% | +160.94% | n/a |
| Lokelma Revenue | 100M | 39M | 51M | 96M |
| Lokelma Revenue Growth | +156.41% | -23.53% | -46.88% | n/a |
| Lynparza Revenue | 717M | 312M | 680M | n/a |
| Lynparza Revenue Growth | +129.81% | -54.12% | n/a | n/a |
| Nexium Revenue | 248M | 30M | 1.31B | n/a |
| Nexium Revenue Growth | +726.67% | -97.70% | n/a | n/a |
| Oncology, Others Revenue | 54M | 1M | 244M | n/a |
| Oncology, Others Revenue Growth | +5300.00% | -99.59% | n/a | n/a |
| Onglyza Revenue | 65M | 22M | 1M | n/a |
| Onglyza Revenue Growth | +195.45% | +2100.00% | n/a | n/a |
| Other, Others Revenue | 53M | 6M | 24M | n/a |
| Other, Others Revenue Growth | +783.33% | -75.00% | n/a | n/a |
| Pulmicort Revenue | 124M | 15M | n/a | n/a |
| Pulmicort Revenue Growth | +726.67% | n/a | n/a | n/a |
| Respiratory, Others Revenue | 71M | 46M | n/a | n/a |
| Respiratory, Others Revenue Growth | +54.35% | n/a | n/a | n/a |
| Roxadustat Revenue | 73M | 50M | n/a | n/a |
| Roxadustat Revenue Growth | +46.00% | n/a | n/a | n/a |
| Saphnelo Revenue | 68M | 223M | n/a | n/a |
| Saphnelo Revenue Growth | -69.51% | n/a | n/a | n/a |
| Seloken-Toprol-XL Revenue | 164M | 574M | n/a | n/a |
| Seloken-Toprol-XL Revenue Growth | -71.43% | n/a | n/a | n/a |
| Soliris Revenue | 814M | 193M | n/a | n/a |
| Soliris Revenue Growth | +321.76% | n/a | n/a | n/a |
| Strensiq Revenue | 300M | 222M | n/a | n/a |
| Strensiq Revenue Growth | +35.14% | n/a | n/a | n/a |
| Symbicort Revenue | 600M | 2M | n/a | n/a |
| Symbicort Revenue Growth | +29900.00% | n/a | n/a | n/a |
| Synagis Revenue | 87M | 513M | n/a | n/a |
| Synagis Revenue Growth | -83.04% | n/a | n/a | n/a |
| Tagrisso Revenue | 1.49B | 1.6B | n/a | n/a |
| Tagrisso Revenue Growth | -7.10% | n/a | n/a | n/a |
| Total Oncology Revenue | 4.38B | 36M | n/a | n/a |
| Total Oncology Revenue Growth | +12072.22% | n/a | n/a | n/a |
| Total Other medicines Revenue | 301M | 236M | n/a | n/a |
| Total Other medicines Revenue Growth | +27.54% | n/a | n/a | n/a |
| Ultomiris Revenue | 713M | 3M | n/a | n/a |
| Ultomiris Revenue Growth | +23666.67% | n/a | n/a | n/a |
| Vaxzevria Revenue | 28M | 18M | n/a | n/a |
| Vaxzevria Revenue Growth | +55.56% | n/a | n/a | n/a |
| Zoladex Revenue | 233M | 23M | n/a | n/a |
| Zoladex Revenue Growth | +913.04% | n/a | n/a | n/a |
| Andexxa Revenue | 45M | 1M | n/a | n/a |
| Andexxa Revenue Growth | +4400.00% | n/a | n/a | n/a |
| FluMist Revenue | 3M | n/a | n/a | n/a |
| FluMist Revenue Growth | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 30, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 5.01B | 4.57B | 5.55B | 5.29B | 5.06B | 4.63B | 3.98B | 4.93B | 5.12B | 4.19B | 4.78B | 4.4B | 4.81B | 4.96B | 5.24B | 2.99B | 3.2B | 3.03B | 3.32B | 2.27B | 2.74B | 2.81B | 3.09B | 3.25B | 3.02B | 2.59B | 2.69B | 2.5B | 2.63B | 2.54B | 2.29B | 2.57B | 2.43B | 2.38B | 1.47B | 2.48B | 3.14B | 2.65B | 2.77B | 2.76B | 3.05B | 2.88B |
| Selling, General, and Administrative Revenue Growth | +9.47% | -17.63% | +5.01% | +4.49% | +9.31% | +16.24% | -19.19% | -3.67% | +22.04% | -12.23% | +8.49% | -8.46% | -3.12% | -5.27% | +75.52% | -6.72% | +5.71% | -8.77% | +46.21% | -17.12% | -2.39% | -9.25% | -4.86% | +7.47% | +16.67% | -3.75% | +7.89% | -5.28% | +3.82% | +10.78% | -10.96% | +5.88% | +2.23% | +61.81% | -40.74% | -21.13% | +18.69% | -4.30% | +0.33% | -9.57% | +6.05% | n/a |
| Research and Development Revenue | 3.55B | 3.16B | 4.68B | 3.12B | 3.01B | 2.78B | 3.07B | 2.58B | 2.67B | 2.61B | 2.63B | 2.36B | 2.55B | 2.13B | 2.58B | 2.15B | 1.83B | 1.71B | 1.72B | 1.45B | 1.39B | 1.39B | 2.07B | 1.33B | 1.36B | 1.27B | 2.01B | 1.28B | 1.36B | 1.28B | 1.55B | 1.4B | 1.35B | 1.45B | 1.54B | 1.4B | 1.47B | 1.48B | 1.75B | 1.43B | 1.47B | 1.36B |
| Research and Development Revenue Growth | +12.31% | -32.46% | +50.14% | +3.56% | +8.08% | -9.44% | +18.92% | -3.11% | +2.14% | -0.53% | +11.37% | -7.42% | +19.36% | -17.45% | +20.07% | +17.66% | +6.77% | -0.35% | +18.31% | +4.61% | +0.07% | -33.01% | +56.02% | -2.06% | +7.11% | -37.08% | +57.31% | -6.09% | +6.49% | -17.54% | +10.47% | +4.08% | -7.16% | -5.83% | +10.06% | -4.30% | -1.01% | -15.23% | +22.18% | -2.52% | +8.11% | n/a |
| Sales and Marketing Revenue | 143M | 132M | 143M | 145M | 132M | 135M | 17.83B | 129M | 131M | 134M | 4.78B | 126M | 4.81B | 4.96B | 5.24B | 2.99B | 3.2B | 3.03B | 3.32B | 2.27B | 2.74B | 2.81B | 3.09B | 3.25B | 3.02B | 2.59B | 2.69B | 2.5B | 2.63B | 2.54B | 85M | 76M | 72M | 77M | 83M | 76M | 3.14B | 2.65B | 2.77B | 2.76B | 3.05B | 2.88B |
| Sales and Marketing Revenue Growth | +8.33% | -7.69% | -1.38% | +9.85% | -2.22% | -99.24% | +13720.16% | -1.53% | -2.24% | -97.19% | +3691.27% | -97.38% | -3.12% | -5.27% | +75.52% | -6.72% | +5.71% | -8.77% | +46.21% | -17.12% | -2.39% | -9.25% | -4.86% | +7.47% | +16.67% | -3.75% | +7.89% | -5.28% | +3.82% | +2885.88% | +11.84% | +5.56% | -6.49% | -7.23% | +9.21% | -97.58% | +18.69% | -4.30% | +0.33% | -9.57% | +6.05% | n/a |